

Form Name: PMPRB Guideline Consultation Form - EN
Submission Time: July 30, 2020 9:50 am
Browser: Chrome 84.0.4147.89 / Windows
IP Address: 78.129.10.91
Unique ID: 641350137
Location: 50.833301544189, 4.3667001724243

Name	Emanuele Degortes
Organization	Vifor Pharma
Email	emanuele.degortes@viforpharma.com
Job Title	Head of Patient, Innovation and Access Policy
Address	Zurich

Vifor Pharma is a Swiss Headquartered company with a global reach. We are a global leader in iron deficiency and iron deficiency anemia therapies and, building on our history, we have used our expertise in research and development, in-licensing, manufacturing, regulatory affairs and commercialization to expand into the complementary fields of nephrology and cardio-renal therapies.

As we expand our geographic reach, Canada is one of the key markets we are looking at in the launch of our future products through licensing partnerships.

The current discussions on the review of the PMPRB guidelines however have created some uncertainty.

While Canada has traditionally been recognized as a top tier country for investment and timely product launches, the growing complexities and increased restrictions of the pricing system which the new guidelines propose is making it harder to assess opportunities in Canada.

The changes proposed are indeed significant and, as a foreign company looking to invest in Canada and needing to balance out different considerations from a global perspectives, they change the underlying assumptions of the commercial viability of our future product launches.

The Canadian HTA process and pricing regulations are already complex compared to other systems around the world. We would therefore urge the authorities to carefully consider introducing additional burdens on innovative companies wishing to introduce new therapies in the Canadian market to help patients lead healthier and better lives.